Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Photophobia, Pyrexia, Sensitive skin, Vision blurred
Clinical narrative: Body chills, fever, stomachpain, nauseous, fatigue and headacheat various times for rest ofday/night/next day.; Body chills, fever, stomachpain, nauseous, fatigue and headacheat various times for rest ofday/night/next day.; Body chills, fever, stomachpain, nauseous, fatigue and headacheat various times for rest ofday/night/next day.; Body aches, chills, skin sensitivity fever, very bad headache with light sensitivity and trouble focusing eyes; Body aches, chills, skin sensitivity fever, very bad headache with light sensitivity and trouble focusing eyes; Body aches, chills, skin sensitivity, fever, very bad headache with light sensitivity and trouble focusing eyes; Body aches, chills, skin sensitivity, fever, very bad headache with light sensitivity and trouble focusing eyes; Body aches, chills, skin sensitivity, fever, very bad headache with light sensitivity and trouble focusing eyes; Body aches, chills, skin sensitivity, fever, very bad headache with light sensitivity and trouble focusing eyes; Body aches, chills, skin sensitivity, fever, very bad headache with light sensitivity and trouble focusing eyes; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 MRNA vaccine; Lot number: EP6955) via an unspecified route of administration in the left arm on 01Apr2021 at 10:30 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Medical history included previous lobular carcinoma in-situ pronounced clear in Dec2020, environmental allergies and penicillin allergy. Concomitant medications included tamoxifen (MANUFACTURER UNKNOWN) for previous Lobular carcinoma in-situ; loratadine (MANUFACTURER UNKNOWN) and vitamin d nos (VIT D) (prescribed); for unknown indications and from unknown dates. The patient previously received erythromycin (MANUFACTURER UNKNOWN) and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 MRNA vaccine; Lot number: EL3247) via an unspecified route of administration in the left arm on 11Mar2021 at 10:30 (at the age of 50-years-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine.  On 01Apr2021, 12 hours after vaccination the patient experienced body aches, chills, skin sensitivity, fever, very bad headache with light sensitivity and trouble focusing eyes from Thursday night to Friday night. On Saturday 03Apr2021 by 10:00, the patient felt better but had body chills, fever, stomach pain, nauseous, fatigue and headache at various times for the rest of the day/night and the next day. On Monday 05Apr2021, the patient felt somewhat better, slightly nauseous and fatigued. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported events. The clinical outcome of the event body aches, chills, skin sensitivity, fever, headache, light sensitivity to eyes, difficulty focusing eyes, stomach pain, nausea and fatigue was resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.